The
drug screening market is expected to reach USD 8.63 Billion by 2022 from
USD 5.32 Billion in 2017, at a CAGR of 10.2%.
Factors such as growing drug & alcohol consumption,
enforcement of stringent laws mandating drug and alcohol testing, and the
availability of government funding in major markets are driving the growth of
this market.
Download PDF
Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773
Drug screening market
segmentation:
• based on
products
• based on
diseases
• based on
techniques,
• based on
end users
• based on
regions.
The Major Players
Opearting in the Drug screening Market:
Most key players adopted product launches as the primary
growth strategy between 2014 and 2017. Some of the companies that adopted this
strategy include Alfa Scientific Designs, Thermo Fisher, and Premier Biotech.
Geographical Detailed
Analysis for Drug screening Market:
North America is expected to dominate the market followed by
Europe. The large share of this geographical segment is attributed to factors
such as growing consumption of illicit drugs, the availability of government
funding to curb drug addiction, presence of laws supporting drug screening, and
growing burden of road accidents due to alcohol consumption in the region.
The drug screening market is highly competitive with the
presence of several small and big players. Some of the players offering
products for drug screening market include Alere (US), Thermo Fisher (US),
Siemens Healthineers (Germany), Alfa Scientific Designs (US), Roche
(Switzerland), MPD, Inc. (US), Shimadzu (Japan), OraSure (US), Lifeloc (US),
and Drägerwerk (Germany). On the other hand, LabCorp (US), Quest Diagnostics
(US), Psychemedics (US), Omega Laboratories (US), CRL (US), SureHire (Canada),
and CannAmm (Canada).
Read More in Detailed (Drug screening
Market ):
No comments:
Post a Comment